| Field | Specification |
|---|---|
| Target | |
| Alternative names | Prostate-specific antigen;PSA;3.4.21.77;Gamma-seminoprotein;Seminin;Kallikrein-3;P-30 antigen;Semenogelase;KLK3;APS; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human PSA recombinant protein (Position: I25-P261). Human PSA shares 54% amino acid (aa) sequence identity with rat PSA. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets prostate-specific antigen (gene KLK3) in human samples and is validated for IHC and Western blot. The predicted molecular weight is 28.7 kDa, and the supplier reports an observed band at about 29 kDa.
Prostate-specific antigen (PSA, KLK3) is a chymotrypsin-like serine protease secreted by prostate epithelial cells into seminal fluid. It cleaves the semenogelins of the seminal clot, allowing semen to liquefy and sperm to move. PSA levels in blood are widely used in prostate cancer screening and monitoring, making it one of the best-known kallikreins.
| Target | Prostate-specific antigen (gene KLK3; UniProt P07288, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 28.7 kDa |
| Observed MW | 29 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 1–2 µg/mL (Human) |
Samples with a confirmed band (WB): human LNCAP cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human prostatic cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Recombinant human PSA fragment (Ile25–Pro261), expressed in E. coli. Sequence identity with the rat ortholog: 54%.
Reactivity Notes
The supplier lists reactivity with human. UniProt describes prostate-specific antigen as a secreted protein. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Bo-Ram Jin et al. (2023) Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR–NLRP3 pathway. Redox Biology. 10.1016/j.redox.2023.102816
Bo-Ram Jin et al. (2025) Hot melt extrusion-enhanced Angelica gigas alleviates benign prostatic hyperplasia via AR/ERK signaling: A network pharmacology-based mechanistic study. Phytomedicine. 10.1016/j.phymed.2025.157530
Hyo-Jung Kim et al. (2023) Hesperidin ameliorates benign prostatic hyperplasia by attenuating cell proliferation, inflammatory response, and epithelial-mesenchymal transition via the TGF-β1/Smad signaling pathway. Biomedicine & Pharmacotherapy. 10.1016/j.biopha.2023.114389
Hyo-Jung Kim et al. (2021) Umbelliferone Ameliorates Benign Prostatic Hyperplasia by Inhibiting Cell Proliferation and G1/S Phase Cell Cycle Progression through Regulation of STAT3/E2F1 Axis. International Journal of Molecular Sciences. 10.3390/ijms22169019
Bo-Ram Jin et al. (2020) Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis. Aging-US. 10.18632/aging.102731
Bo-Ram Jin et al. (2020) Anti-Proliferative Effects of Standardized Cornus officinalis on Benign Prostatic Epithelial Cells via the PCNA/E2F1-Dependent Cell Cycle Pathway. International Journal of Molecular Sciences. 10.3390/ijms21249567
Hyo-Jung Kim et al. (2021) Psoralea corylifolia L. extract ameliorates benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis. Journal of Ethnopharmacology. 10.1016/j.jep.2021.113844
Bo-Ram Jin et al. (2019) 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway. Nutrients. 10.3390/nu11092203
Subin Oh et al. (2022) A Combination of Natural Products, BenPros (Green Tea Extract, Soybean Extract and Camellia Japonica Oil), Ameliorates Benign Prostatic Hyperplasia. Applied Sciences-Basel. 10.3390/app12126121
